HB-adMSCs

BIOLOGICAL20 trials

Sponsors

Hope Biosciences LLC, Hope Biosciences Research Foundation

Conditions

Alzheimer DiseaseAmyotrophic Lateral SclerosisCOVID-19Cerebral PalsyChronic Inflammatory Demyelinating PolyneuropathyCongenital Muscular Dystrophy Due to Lamin A/C MutationMultiple SclerosisPancreatic Cancer

Phase 1

Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

CompletedNCT03691909

Hope Biosciences LLCRheumatoid Arthritis

Start: 2018-09-25End: 2020-09-28Updated: 2025-09-26

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

CompletedNCT04063215

Hope Biosciences LLCTraumatic Brain Injury

Start: 2020-01-01End: 2024-10-25Updated: 2026-01-15

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease

WithdrawnNCT04228666

Hope Biosciences LLCAlzheimer Disease

Start: 2020-03-01End: 2022-02-01Updated: 2025-09-29

Phase 2

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

CompletedNCT04348435

Hope Biosciences Research FoundationCOVID-19

Start: 2020-05-14End: 2021-05-12Updated: 2025-09-26

A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19

CompletedNCT04349631

Hope Biosciences Research FoundationCOVID-19

Start: 2020-04-20End: 2020-11-25Updated: 2025-09-26

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

CompletedNCT04928287

Hope Biosciences Research FoundationParkinson Disease

Start: 2021-06-28End: 2023-02-06Updated: 2026-04-15

Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis

CompletedNCT05116540

Hope Biosciences Research FoundationMultiple Sclerosis

Start: 2021-11-24End: 2024-06-04Updated: 2025-09-26

Unknown Phase

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI

Hope Biosciences LLCSpinal Cord Injury at C5-C7 Level

Updated: 2025-09-29

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

Hope Biosciences Research FoundationCerebral Palsy

Updated: 2025-09-29

Individual Patient Expanded Access IND to Treat Polyneuropathy

Hope Biosciences Research FoundationPolyneuropathies

Updated: 2025-09-29

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord Injury

Hope Biosciences Research FoundationSpinal Cord Injuries

Updated: 2025-09-29

Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer

Hope Biosciences LLCPancreatic Cancer

Updated: 2025-09-29

Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis

Hope Biosciences Research FoundationAmyotrophic Lateral Sclerosis

Updated: 2025-09-29

Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.

Hope Biosciences Research FoundationParkinson Disease

Updated: 2025-09-29

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

Hope Biosciences Research FoundationPost COVID-19 Syndrome

Updated: 2025-09-29

An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Hope Biosciences Research FoundationChronic Inflammatory Demyelinating Polyneuropathy

Updated: 2025-09-29

Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis

Hope Biosciences Research FoundationPrimary Lateral Sclerosis, Adult, 1

Updated: 2025-09-29

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

Hope Biosciences Research FoundationSystem; Lupus Erythematosus

Updated: 2025-09-29

Individual Patient Expanded Access IND for the Treatment of Stroke

Hope Biosciences Research FoundationStroke, Stroke, Ischemic

Updated: 2025-09-29

HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.

Hope Biosciences Research FoundationCongenital Muscular Dystrophy Due to Lamin A/C Mutation

Updated: 2025-09-29

Related Papers

Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program

Stem Cell Research & Therapy2023-10-057 citations

Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial.

2022-03-0334 citations